3759
vs
H
Hang Seng (Hong Kong)
3759
Over the past 12 months, Pharmaron Beijing Co Ltd has outperformed Hang Seng (Hong Kong), delivering a return of +25% compared to the Hang Seng (Hong Kong)'s +16% growth.
Stocks Performance
3759 vs Hang Seng (Hong Kong)
Performance Gap
3759 vs Hang Seng (Hong Kong)
Performance By Year
3759 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Pharmaron Beijing Co Ltd
Glance View
Pharmaron Beijing Co Ltd., a dynamic player in the biotech and pharmaceutical services sector, has carved a niche by capitalizing on the demand for comprehensive R&D services. Founded in 2004, the company emerged at a time when global pharmaceutical companies were grappling with skyrocketing research costs and the increasing complexity of drug development. Pharmaron offers a broad spectrum of services across the drug discovery and development pipeline, including laboratory services, chemistry, biology, and pharmacology, effectively monetizing its expertise by partnering with global pharmaceutical firms. By providing integrated solutions that cover the entire span of research, from preclinical development to commercial manufacturing, Pharmaron positions itself as an indispensable ally for companies aiming to streamline their product development journeys. The company’s revenue model thrives on long-term partnerships and collaborations with some of the industry's leading pharmaceutical and biotech firms. Using a client-centric approach, Pharmaron aligns its capabilities with customer needs, ensuring scalable and customizable service offerings. This close alignment not only enhances client satisfaction but also encourages repeat business, fostering a cycle of sustainable revenue growth. In recent years, Pharmaron has been expanding its geographical footprint and service capacity through strategic acquisitions and investments in state-of-the-art facilities and technologies, aiming to bolster its position in key markets across the US, Europe, and China. As the pharmaceutical landscape continues to evolve, Pharmaron leverages its robust R&D service portfolio and strategic alliances to maintain its growth trajectory amidst a backdrop of increasing globalization and technological advancement in the industry.
